Monitoring treatment for osteoporosis by using bone densitometry

Seminars in Nuclear Medicine

Volumn 31, Issue 3, 2001, Pages 212-222

  Blake, Glen M ^a   Fogelman, Ignac ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE DENSITY; BONE MINERAL; BONE SCINTISCANNING; CALCITONIN BLOOD LEVEL; DENSITOMETRY; DIAGNOSTIC ACCURACY; ERROR; ESTROGEN BLOOD LEVEL; FOLLOW UP; HISTOGRAM; HORMONE SUBSTITUTION; HUMAN; OSTEOPOROSIS; PATIENT MONITORING; PROGESTERONE BLOOD LEVEL; PROPHYLAXIS; REVIEW;

EID: 0034980432     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2001.23528     Document Type: Article

References (68)

1. Guidelines for diagnosis and treatment of osteoporosis
2. Hip fractures in the elderly: A world-wide projection
3. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation
4. Costs and health effects of osteoporotic fractures
5. Treatment of postmenopausal osteoporosis
6. Treatment of postmenopausal osteoporosis with transdermal oestrogen
7. 3 and calcium to prevent fractures in elderly women
8. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
9. Effects of raloxifine on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
10. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
11. Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence
12. Hormone therapy to prevent disease and prolong life in postmenopausal women
13. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis
14. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
15. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial
16. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomised trial
17. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis
18. Diagnosis and management of osteoporosis: Guidelines for the utilization of bone densitometry
19. Interpretation of bone densitometry studies
20. Fracture risk as determined by prospective and retrospective study designs
21. Which fractures are associated with low appendicular bone mass in elderly women?
22. Bone density at various sites for prediction of hip fractures
23. Long-term fracture prediction by bone mineral assessed at different skeletal sites
24. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
25. A single bone density measurement can predict fractures over 25 years
26. Assessment of fracture risk by bone density measurements
27. Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis
28. Discordance in patient classification using T-scores
29. Do we need to change the WHO definition of osteoporosis?
30. Controversies in bone mineral density diagnostic classifications
31. Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound?
32. Ultrasonographic heel measurements to predict hip fracture in elderly women: The EPIDOS prospective study
33. Broadband ultrasonic attenuation predicts fractures strongly and independently of densitometry in older women
34. Ultrasound measurements for the prediction of osteoporotic fractures in elderly people
35. Alendronate prevents postmenopausal bone loss in women without osteoporosis: A double-blind, randomized, controlled trial
36. Prevention of bone loss in postmenopausal women under 60 years of age
37. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures
38. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: Results from the Fracture Intervention Trial
39. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
40. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis
41. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
42. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
43. Effect of risedronate treatment on hip fracture risk in elderly women
44. Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean
45. Accurate assessment of precision errors: How to assess the reproducibility of bone densitometry techniques
46. Impact of soft tissue on in vivo accuracy of bone mineral measurements in the spine, hip, and forearm: A human cadaver study
47. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women
48. Long-term prevention of postmenopausal osteoporosis by estrogen. Evidence for an increased bone mass after delayed onset of estrogen treatment
49. Prevention of early postmenopausal bone loss: Controlled 2-year study in 315 normal females
50. Cyclical editronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment
51. Skeletal benefits of alendronate: 7-Year treatment of postmenopausal osteoporotic women
52. Effects of baseline BMD, age, and prevalent vertebral fractures on the response of osteoporotic patients to LY333334 [rhPTH(1-34)]
53. The effect of weight change on total body dual x-ray absorptiometry: Results from a clinical trial
54. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
55. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis
56. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVOS study
57. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs
58. How much of the reduction of vertebral fractures by alendronate is explained by increased spine BMD?
59. Predicting the effect of antiresorptive treatments on risk of vertebral fractures: A meta-analysis
60. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
61. Antifracture efficacy of antiresorptive drugs are related to changes in bone density
62. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
63. Monitoring skeletal response to therapy in early postmenopausal women: Which bone to measure?
64. A longitudinal study of supine lateral DXA of the lumbar spine: A comparison with posteroanterior spine, hip and total body DXA
65. Bone densitometry: Choosing the proper skeletal site to measure
66. Are nonresponders responding?
67. Long-term compliance with hormone replacement treatment following screening for postmenopausal osteoporosis by bone density measurement